

Grape King Bio(1707 TT) Investor Presentation

Apr 2021

Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



Company Background

Confidential

Investment Highlights



- ✓ We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2019.
- We operate the second largest direct-selling company Pro-Partner in Taiwan (2019 market share: 8.3%).





- We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- Our expertise in raw materials allow us to develop health supplements serving different benefits.
 Therefore, many of our products are TFDA approved for different health benefits.
- We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.





- ✓ We have delivered a solid earnings during 2008-2020 (CAGR of 19%/average ROE 25%).
- We have maintained more than 60% dividend payout in the past five years.
- On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.

Company Milestones


Grape King is selected as Grape King Bio-Tech Research Forbes "Asia's 200 Best Under Institute was established. A Billion." for two consecutive 1991 years. Grape King formed a joint ٠ **Bio Engineering Center was** venture with All Cosmos Bio-2014 established. Tech Holding Corp (4148 TT) to Dr. Andrew Tseng succeeded set up GK Bio International to 2017 his father to become the CEO 1982 1997 expand Malaysia market. and Chairman. Grape King's first . Grape King signed a joint Listed on Taiwan Shanghai Grape tourist center Grape King is selected as memorandum with Japanese Stock Exchange King was opened in July. Forbes "Asia's 200 Best Under leading health supplement established. A Billion." OEM/ODM company API Co., Ltd. 1969-Grape King was founded 2009 2013 2016 2020 1993 Pro-Partner's ranked Pro-Partner's ranked Grape King Bio-Tech Grape King Bio-Tech No.6 among Taiwan No.3 among Taiwan Headquarter started Pro-Partner was formed a strategic direct selling direct selling established. operation in September. alliance with TST - a companies. 2008 2012 companies. leading social-selling 2014 company in China. Pro-Partner's ranked Pro-Partner's ranked Pro-Partner's ranked 2018 No.8 among Taiwan No.4 among Taiwan No.2 among Taiwan direct selling companies. direct selling Taipei Grape King direct selling companies. Sales headquarter companies.

2015

was established.

2019

Company Overview : Three core business units



2020 REVENUE

1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM

Locus of all key ingredient design, formulation, and production for the whole Group.

2. Pro-Partner (60%-own) Taiwan direct selling distribution

A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.

3. Grape King Shanghai (100%-own) China OEM & ODM


Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.

Complete Product Range



Competitive Strengths - Strong Products Capabilities

We acquired more than 186 patents and published over 84 research papers. Also, we acquired more than 10 TFDA Health Food certifications on our products.



Grape King Biotech Research Institute Product Innovation backed by Science

Fermented Cordyceps cicadae mycelia extracts ameliorate dry eye symptoms in the mouse dry eye model







2017~2020 : 8 countries, 125 awards



Competitive Strengths - State-of-the-Art Production Facilities

150 Liters Freeze-Dryer

Fermentor

Shaker


We have the largest fermentation capacity (386 tons) among all the health food companies in Asia.

Sachet Packaging Line

Glass Bottle Packaging Line

1. Grape King Taiwan

"





Metabolism promotion and digestion/defecation improvement

Energy drinks that restore energy and provides necessary vitamins

Our third best seller – Probiotics King 13% of 2020 revenue

30包入 6

全面守護消化道 健康順暢每一天

益菌王

調整體質維持消化這機能 化進化器·於關係器含無 壞的進不來

Liver protection and hangover prevention and alleviation

Improves digestion and defecation

Antrodia King 9% of 2020 revenue

Our fourth best seller –



"



Pro-Partner Overview



3,690 m

1,960 m

 No. 49 in the worldwide direct selling company rankings for 2018

(Source: 2019 DSN Global 100- based on 2018 revenues)

Sales (NT\$)

Our best seller – Probiotics & Prebiotics 29% of 2020 revenue Our second best seller – Bio Aid 995 15% of 2020 revenue


ADMIC MIRRINIE 28

Bio Aid

Promote healthy digestive system and suppress allergy

康爾喜N

康爾喜



Bai Yi Jie (toothpaste)



Grape King's Lactobacillus pentosus GK4

- → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol
 - → Anti-plaque

Sodium fluoride

- → Prevent enamel erosion
- Mint
 - \rightarrow Sooth teeth

Hi Spray (oral spray)

- Grape King's Lactobacillus pentosus GK4
 - → Inhibit 13 kinds of oral bacteria & Prevent cavities


Life Spray Anna

清新國黨

- Sorbitol → Anti-plaque
- Thyme → Freshen breath
- Mint → Sooth teeth


How is Pro-Partner different from other direct selling companies?

Nearly 80% of Pro-Partner's sales are contributed by old members



Healthy membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group.



How is Pro-Partner different from other direct selling companies?



company.





"

3. Grape King Shanghai



Grape King Shanghai Overview

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.



Grape King Shanghai operating profit (Rmb m)





General foods PKL Health Beauty Energy supplements drinks supplements drinks drink

*In 2019, the overall demand was impacted by China government's tightening on direct-selling and healthcare industry & in 2020 the China consumption recovery has been softer-than-expected under the pandemic.



Our Goals and Strategies

Confidential

Growing our online sales channel





Besides our existing physical retail channels, we are increasing our virtual channel penetration.

Our Virtual channel

- ✓ Grape King online store
- ✓ Online B2C stores
- TV shopping channels
- Social Media

Creative Brand Building



Grape King Antrodia King (liver protection) Stress causes high blood pressure but also harms liver

Creative Brand Building

促進代謝·改變菌叢生的

30包入

葡萄王 益菌王 粉末顆粒 十年熱銷品牌 葡萄 促進代謝·改變菌叢生態 益菌王 紛末顆粒

Grape King Probiotics

Probiotics like a golden warrior who protects your digestion

Our Capacity and Expansion Plan Grape King Specialist Fermentation Grape King Shanghai Grape King Bio-Tech **Grape King Biotech** & Manufacturing Site* **Headquarters** Headquarter **Research Institute** 19 10 10 **Monthly Capacity** Monthly Capacity **Monthly Capacity** Production Capacity Production Production Start 2019 2019 Line 2019 2020 Line 2019 2020 Capsules 7 M capsules 7 M capsules 18 M bottles Liquids(Glass) 18 M bottles 13M Capsules 13M capsules Fine Granule capsules 2 M pack 2 M pack Liquids Lactobacilli 40 tons 40 tons 3 M packs 3 M packs (Retort Pouch Liquids-Bia CC 4.2 M bottles 4.2 M bottles Fine Granule 15M pack 15M pack 15 M pack Powder 15 M pack Liquids-Small CC 1 M bottles 1 M bottles Capsules 7 M capsules 7 M capsules PKL 1.4 M bottles 1.4 M bottles Powder 1.8M packs 1.8M packs Mushroom 60 tons 60 tons PIC/S 0.8 M packs 0.8 M packs Troches 63 M capsules 63 M capsules 7.2M packs** 3020 Jelly foil **Monthly capacity =30.000 packs/hr x 12 hrs/day x 20 working days/month Production Capacity 2019 **FSSC** 22000 **FA** Lactobacilli 25 tons 25 tons PIC/S GM Mushroom 161.5 tons 161.5 tons SGS **Testing Laboratory** GMP Registered **PKL Liquids** 80 tons 80 tons 3129 *Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin

in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in revenue for Grape King.

* We expect to spend NT\$ 680m capex in 2021 for new plant building and equipment purchases (NT\$ 360m), product line expansion of Biotech Research Institute (NT\$ 180m) and product line expansion for Specialist Fermentation & Manufacturing Site and Bio-Tech Headquarter.

Our Goal

To become a global leading health and wellness company that promotes a healthier living and a more sustainable future

" **Our Product Development Focus**











Our Growth Strategies

Key Objectives

Grape King Taiwan

- Market share gain
- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

Pro-Partner

- Unlock growth ceiling
- Improving demand forecast,
- sales visibility, and products time to market

Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom

Levers


- Market share gain through products upgrade and deeper channels penetration
- Business expansion through penetrating new product categories
- Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- ✓ Focus on growing younger members.
- Duplicate Taiwan success in new geographies
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- ✓ Develop non-direct/WeChat customers
- Capture more business opportunities through local strategic partnerships and alliances

Sustainable topline and bottomline growth



02

Unleash growth potential through expanding into new adjacencies



Consumers are looking for a healthier approach to beauty and personal care

Significant physiological similarities between humans and pets

Growing on Giant's Shoulder




Taiwan/overseas mutual OEM production

• Food safety enhancement

Our Sustainability Initiatives

2019





Financial Performance


Confidential

Financial Highlights



Historical revenue vs. operating profit


Historical gross margin vs. operating margin




----Gross margin (LHS) -----Operating margin

Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.

Historical EPS vs. ROCE




Historical cash dividend payout



Revenue Breakdown (2020 v.s. 2019)

2020 REVENUE



1.Grape King Taiwan NT\$ 668 m (+24% YoY)

Thanks to strong sales of our own brand products as well as higher ODM revenues.


2.Pro-Partner NT\$ 7,719 m (-1% YoY)

Though the limitation on physical activities impacted operation in 1H20, the sales improved follow the activities resume in 2H20.

3.Grape King Shanghai NT\$ 781 m (-14% YoY)

China consumption recovery has been softerthan-expected. However our current order visibility prior to the Chinese New Year has remained decent.

2019 REVENUE



Grape King Taiwan Pro-Partner Grape King Shanghai

Five-Year Income Statement

(NT\$ m)	2015 2016	2014	5 2017	2018	2019	2020	YoY (%)					
		2010					2015	2016	2017	2018	2019	2020
Revenue	7,248	9,185	9,388	9,183	9,239	9,168	15.4	26.7	2.2	(2.2)	0.6	(0.8)
Gross Profit	6,385	7,919	7,865	7,329	7,566	7,537	14.8	24.0	(0.7)	(6.8)	3.2	(0.4)
Operating Expenses	(4,573)	(5,685)	(5,610)	(4,979)	(5,231)	(5,232)	15.4	24.3	(1.3)	(11.2)	5.0	0.0
Operating Profit	1,812	2,234	2,254	2,350	2,335	2,305	13.3	23.3	0.9	4.2	(0.6)	(1.3)
Non Operating Income/(Loss)	70	78	151	77	105	73	(21.5)	11.8	92.6	(49.2)	36.8	(30.2)
Pretax Income	1,883	2,312	2,405	2,427	2,440	2,378	11.4	22.8	4.0	0.9	0.6	(2.5)
Tax Expenses	(336)	(426)	(471)	(537)	(502)	(483)	10.9	26.8	10.6	14.0	(6.5)	(3.7)
Minority interest	(495)	(590)	(583)	(595)	(630)	(623)	11.5	19.2	(1.3)	2.1	5.9	(1.1)
Net Income to Parent	1,052	1,297	1,352	1,295	1,309	1,272	11.6	23.3	4.3	(4.2)	1.1	(2.8)
Basic EPS (NT\$)	8.07	9.82	10.03	9.57	9.63	9.34	11.5	21.7	2.1	(4.6)	0.6	(3.0)
Key Financial Ratios (%)												
Gross Margin	88.1	86.2	83.8	79.8	81.9	82.2						
Operating Expense Ratio	63.1	61.9	59.8	54.2	56.6	57.1						
Operating Margin	25.0	24.3	24.0	25.6	25.3	25.1						
Effect Tax Rate	17.8	18.4	19.6	22.1	20.6	20.3						
Net Margin	14.5	14.1	14.4	14.1	14.2	13.9						

Five-Year Balance Sheet

(NT\$ m)	2015	2016	2017	2018	2019	2020	YoY (%)					
							2015	2016	2017	2018	2019	2020
Total Assets	8,612	9,550	9,892	10,648	11,359	13,104	60.4	10.9	3.6	7.6	6.7	15.4
Cash	1,433	1,899	1,920	2,050	2,146	2,927	4.3	32.6	1.1	6.8	4.7	36.4
AR & NR	97	204	160	171	202	202	(1.9)	111.6	(21.5)	6.8	18.0	(0.2)
Inventories	359	435	492	563	546	689	34.0	21.0	13.1	14.4	(2.9)	26.2
Fixed Assets	5,597	6,084	6,355	5,927	6,454	7,308	170.6	8.7	4.5	(6.7)	8.9	13.2
Total Liabilities	4,393	3,767	3,564	3,715	3,888	5,126	165.9	(14.3)	(5.4)	4.2	4.7	31.8
AP & NP	153	198	323	262	223	255	19.2	29.6	63.2	(18.9)	(15.1)	14.7
Total Borrowing	2,439	1,206	1,022	1,119	1,177	1,921	-	(50.6)	(15.2)	9.5	5.2	63.3
Total Equity	4,220	5,783	6,328	6,933	7,471	7,978	13.5	37.1	9.4	9.6	7.8	6.8
Key Financial Ratios (%)												
A/R Turnover Days	4.8	5.9	7.0	6.5	7.3	7.9						
Inventory Turnover Days	131.0	113.0	109.5	102.4	119.3	136.4						
A/P Turnover Days	58.6	49.9	61.6	56.8	52.2	52.7						
Cash Conversion Days	77.2	69.0	54.9	52.1	74.4	91.6						
ROE (%)	32.1	31.3	27.0	23.7	22.0	19.9						
ROA (%)	15.0	14.3	13.9	12.6	11.9	10.4						
Net debt (cash)/Equity %	23.9	(12.0)	(14.2)	(13.4)	(13.0)	(12.6)						

Dividend Payout and Capex

(NT\$ m)	2015	2016	2017	2018	2019	2020
Net profit	1,052	1,297	1,352	1,295	1,309	1,272
Cash dividend	730	862	903	883	884	948
DPS (NT\$)	5.6	6.4	6.7	6.5	6.5	6.4
Payout ratio	69.4%	65.2%	66.6%	67.9%	67.4%	68.5%
Cash yield	2.6%	3.2%	2.9%	3.0%	3.3%	3.6%
Сарех	2,635	736	772	1,116	630	1,214

Notes:

1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.

2. The capex for 2020 is mainly used for land acquisition for our Zhongli plant relocation and for new production facilities.

3. 2020 cash yield is calculated based on Grape King's 2021/3/2 closing share.



Appendix: Industry Trends

Confidential


Taiwan health food industry

Taiwan's health food industry is growing

Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.

We keep gaining market share in Taiwan

We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.



Grape King's market share in Taiwan health food industry


	<u>2013</u>		2019
Faiwan health food	4.90%	-	5.60%
Mushroom	32.06%	-	44.93%
Probiotics	13.89%	-	30.64%
Energy drink	12.23%	-	11.22%
	Source: A	C Nielsen,	Company data

Source: AC Nielsen

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- 1) Reasonable product price (mark-up on pricing);
- 2) Reasonable compensation structure (distribution of profit)

Member's system

According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration Pro-Partner has highest sales per product among top 3 players

		Rank & Market	Member	Sales contribution			
TOP10	10	shares (%)	s ('000)	Per member (NT\$)	Per product (NT\$m)		
55% Pro-Partner Nu Skin Amway	Pro-Partner	2 (9.8%)	200	43,300	288.7		
	3 (5.5%)	120	40,000	21.9			
	Amway	1 (13.4%)	350	33,857	41.0		


China health food industry

China's health food industry grew 21% CAGR between 2011-2018

China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 7 years.

China direct selling has significant growth from 2011-2018

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 47% in 2018.




Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.

China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



*Notes: Global probiotics market includes probiotics supplement, probiotic yoqhurt, and sour milk products.

Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.



Source: Euromonitor

China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020

China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.

Taiwan and China probiotic supplement market are expected


According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.



yoghurt, and sour milk products.

China Probiotics Market (2014-2020)

Probiotics Supplements Retail Value (2016-2021)





南

Thank You

For more information, please visit our company website at www.grapeking.com.tw



